MARK4 and breast cancer: Considering the critical role of the Hippo/YAP signaling pathway in KMT5A/SNIP1/MARK4-driven breast cancer progression and metastasis, the effects of verteporfin treatment combined with KMT5A-depletion on breast cancer metastasis were assessed.